Suppr超能文献

成人 T 细胞急性淋巴细胞白血病复发的演变。

The evolution of relapse of adult T cell acute lymphoblastic leukemia.

机构信息

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.

Barcelona Institute of Science and Technology (BIST), Baldiri i Reixac 10, 08028, Barcelona, Spain.

出版信息

Genome Biol. 2020 Nov 23;21(1):284. doi: 10.1186/s13059-020-02192-z.

Abstract

BACKGROUND

Adult T cell acute lymphoblastic leukemia (T-ALL) is a rare disease that affects less than 10 individuals in one million. It has been less studied than its cognate pediatric malignancy, which is more prevalent. A higher percentage of the adult patients relapse, compared to children. It is thus essential to study the mechanisms of relapse of adult T-ALL cases.

RESULTS

We profile whole-genome somatic mutations of 19 primary T-ALLs from adult patients and the corresponding relapse malignancies and analyze their evolution upon treatment in comparison with 238 pediatric and young adult ALL cases. We compare the mutational processes and driver mutations active in primary and relapse adult T-ALLs with those of pediatric patients. A precise estimation of clock-like mutations in leukemic cells shows that the emergence of the relapse clone occurs several months before the diagnosis of the primary T-ALL. Specifically, through the doubling time of the leukemic population, we find that in at least 14 out of the 19 patients, the population of relapse leukemia present at the moment of diagnosis comprises more than one but fewer than 10 blasts. Using simulations, we show that in all patients the relapse appears to be driven by genetic mutations.

CONCLUSIONS

The early appearance of a population of leukemic cells with genetic mechanisms of resistance across adult T-ALL cases constitutes a challenge for treatment. Improving early detection of the malignancy is thus key to prevent its relapse.

摘要

背景

成人 T 细胞急性淋巴细胞白血病(T-ALL)是一种罕见疾病,每百万人中发病率不到 10 例。与更为常见的同源儿科恶性肿瘤相比,成人 T-ALL 的研究较少。与儿童相比,更多的成年患者会复发。因此,研究成人 T-ALL 病例复发的机制至关重要。

结果

我们对 19 例成年 T-ALL 患者的初发肿瘤和相应的复发恶性肿瘤进行了全基因组体细胞突变分析,并与 238 例儿科和青年成人 ALL 病例进行了比较,分析了它们在治疗过程中的演变情况。我们比较了初发和复发的成年 T-ALL 中与儿科患者中活跃的突变过程和驱动突变。对白血病细胞中类钟基因突变的精确估计表明,复发克隆的出现发生在初发 T-ALL 诊断前数月。具体来说,通过白血病群体的倍增时间,我们发现,在 19 例患者中的至少 14 例中,在初诊时存在的复发白血病群体包含一个以上但少于 10 个 blast。通过模拟,我们表明,在所有患者中,复发似乎都是由遗传突变驱动的。

结论

在所有成年 T-ALL 病例中,具有耐药遗传机制的白血病细胞群体的早期出现,给治疗带来了挑战。因此,提高对恶性肿瘤的早期检测能力是预防复发的关键。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8330/7682094/c66c452bd87d/13059_2020_2192_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验